Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-19

Clinical Trial Update: Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE) [Phase 3]

View source ↗

Summary

Phase 3 trial update for afamelanotide in polymorphic light eruption has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Afamelanotide (afamelanotide)

Snippet

Sponsor: Clinuvel Pharmaceuticals Limited | Conditions: Polymorphic Light Eruption | Phase 3 | Status: COMPLETED | Results posted: 2021-03-19